The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Aug. 26, 2014
Filed:
Aug. 17, 2009
Milton L. Brown, Brookeville, MD (US);
Scott Grindrod, Arlington, VA (US);
Thomas H. Walls, Arlington, VA (US);
Todd Hansen, Norfolk, VA (US);
Simeng Suy, Fairfax, VA (US);
Mikell A. Paige, Fairfax, VA (US);
Milton L. Brown, Brookeville, MD (US);
Scott Grindrod, Arlington, VA (US);
Thomas H. Walls, Arlington, VA (US);
Todd Hansen, Norfolk, VA (US);
Simeng Suy, Fairfax, VA (US);
Mikell A. Paige, Fairfax, VA (US);
Georgetown University, Washington, DC (US);
Abstract
Disclosed are molecules and their synthesis, for use in blocking gated ion channels such as voltage-gated sodium channels (VGSCs) and prostate voltage sodium channels (PVSCs). These inhibitors have superior blocking efficacy, for instance in displacing the radioligand [H]-Batrachotoxin-B ([H]-BTX-B) that binds to site 2 of a VGSC. The molecules of the invention comprise a moiety which increases the binding affinity of molecules for the protein binding site in prostate cancer cells (PCs), and which is also fluorescent. In one embodiment the invention molecules are an inhibition system that can be used to target over-abundant or hyperactive VGSCs selectively in pain, epilepsy or prostate cancer, inhibiting the proliferation of PCs. The fluorescent moiety also facilitates screening, tracking, and pharmacodynamic studies of the drug in a biological system both in vitro and in vivo.